ABSTRACT
Background: Staphylococcus aureus infections are a significant cause of morbidity and mortality in pediatric populations worldwide. The Staphylo Research Network conducted an extensive study on pediatric patients across Colombia from 2018 to 2021. The aim of this study was to describe the epidemiological and microbiological characteristics of S. aureus in this patient group. Methods: We analyzed S. aureus isolates from WHONET-reporting centers. An "event" was a positive culture isolation in a previously negative individual after 2 weeks. We studied center characteristics, age distribution, infection type, and antibiotic susceptibilities, comparing methicillin sensitive (MSSA) and resistant S. aureus (MRSA) isolates. Results: Isolates from 20 centers across 7 Colombian cities were included. Most centers (80%) served both adults and children, with 55% offering oncology services and 85% having a PICU. We registered 8,157 S. aureus culture isolations from 5,384 events (3,345 MSSA and 1,961 MRSA) in 4,821 patients, with a median age of 5 years. Blood (26.2%) and skin/soft tissue (18.6%) were the most common infection sources. Most isolates per event remained susceptible to oxacillin (63.2%), clindamycin (94.3%), and TMP-SMX (98.3%). MRSA prevalence varied by city (<0.001), with slightly higher rates observed in exclusively pediatric hospitals. In contrast, the MRSA rate was somewhat lower in centers with Antimicrobial Stewardship Program (ASP). MRSA was predominantly isolated from osteoarticular infections and multiple foci, while MSSA was more frequently associated with recurrent infections compared to MRSA. Conclusions: This is the largest study of pediatric S. aureus infections in Colombia. We found MSSA predominance, but resistance have important regional variations. S. aureus remains susceptible to other commonly used antibiotics such as TMP-SMX and clindamycin. Ongoing monitoring of S. aureus infections is vital for understanding their behavior in children. Prospective studies within the Staphylored LATAM are underway for a more comprehensive clinical and genetic characterization.
ABSTRACT
Introduction: Invasive Pneumococcal Disease (IPD) causes significant morbidity and mortality in children under 5 y. Colombia introduced PCV10 vaccination in 2012, and the Neumocolombia network has been monitoring IPD in pediatric patients since 2008. Materials and methods: This study is a secondary analysis of a prospective cohort involving pediatric patients with IPD admitted to 17 hospitals in Colombia, from January 1st, 2017, to December 31st, 2022. We present data on serotypes (Spn), clinical characteristics, and resistance patterns. Results: We report 530 patients, 215 (40.5%) were younger than 24 months. Among these, 344 cases (64.7%) presented with pneumonia, 95 (17.9%) with primary bacteremia, 53 (10%) with meningitis, 6 (1.1%) had pneumonia and meningitis, and 32 (6%) had other IPD diagnosis. The median hospital stay was 12 days (RIQ 8-14 days), and 268 (50.6%) were admitted to the ICU, of whom 60 (11.3%) died. Serotyping was performed in 298 (56.1%). The most frequent serotypes were Spn19A (51.3%), Spn6C (7.7%), Spn3 (6.7%), Spn6A (3.6%), and Spn14 (3.6%). Of 495 (93%) isolates with known susceptibility, 46 (9.2%) were meningeal (M) and 449 (90.7%) non-meningeal (NM). Among M isolates, 41.3% showed resistance to penicillin, and 21.7% decreased susceptibility to ceftriaxone. For NM isolates, 28.2% had decreased susceptibility to penicilin, and 24.2% decreased susceptibility to ceftriaxone. Spn19A showed the highest resistant to penicillin at 47% and was linked to multiresistance. Conclusion: The prevalence of PCV10-included serotypes decreased, while serotypes 19A and 6C increased, with Spn19A being associated with multiresistance. These findings had played a crucial role in the decision made by Colombia to modify its immunization schedule by switching to PCV13 in July 2022.
ABSTRACT
The objective of this article was to consider the vaccination challenges in Colombia and Peru and the role of pediatric combination vaccines in overcoming these challenges. Barriers to including new vaccines with more antigens remain apparent in parts of these countries, where vaccine-preventable diseases in infants continue to be a major problem. The challenges include the heterogeneity of vaccine coverage within each country and in neighboring countries, which can contribute to poor rates of vaccination coverage; the adverse impact of the inward migration of unvaccinated individuals, which has favored the re-emergence of vaccine-preventable diseases; vaccine shortages; and the impact of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic and the associated shifts in health care resources. To improve the coverage of pediatric vaccines in Colombia and Peru, it will be necessary to ensure the widespread integration into vaccine schedules of combination vaccines containing diphtheria, tetanus, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b and hepatitis B antigens with a three-dose primary series delivered at 2, 4 and 6 months of age followed by a booster at 18 months of age. Such vaccines play important roles in preventing diphtheria, tetanus and pertussis; eradicating polio; and providing boosting against H. influenzae type b.
El objetivo de este artículo es considerar los desafíos que se enfrentan en Colombia y Perú con respecto a la vacunación y el papel de las vacunas combinadas pediátricas para superar estos desafíos. Los obstáculos para incluir vacunas nuevas con más antígenos siguen siendo evidentes en algunos lugares de estos países, donde las enfermedades prevenibles por vacunación en menores de 1 año continúan siendo un grave problema. Entre los desafíos se incluye la heterogeneidad de la cobertura de vacunación en cada país y en los países vecinos, lo que puede contribuir con que se registren tasas bajas de cobertura de vacunación; el impacto adverso de la migración interna de personas no vacunadas, lo que ha favorecido la reaparición de enfermedades prevenibles por vacunación; la escasez de vacunas, y el impacto de la pandemia del coronavirus de tipo 2 causante del síndrome respiratorio agudo grave (SARS-CoV-2) y los consiguientes cambios en los recursos de atención médica. Para mejorar la cobertura de las vacunas pediátricas en Colombia y Perú será necesario integrar de manera generalizada en los calendarios de vacunación vacunas combinadas con antígenos de difteria, tétanos, tos ferina acelular, poliovirus inactivados, Haemophilus influenzae tipo b y hepatitis B con una serie primaria de tres dosis administradas a los 2, 4 y 6 meses de edad, seguida de un refuerzo a los 18 meses de edad. Esas vacunas desempeñan un papel esencial en la prevención de la difteria, el tétanos y la tos ferina; la erradicación de la polio; y el refuerzo contra H. influenzae tipo b.
O objetivo deste artigo foi avaliar os desafios da vacinação na Colômbia e no Peru e o papel das vacinas pediátricas combinadas na superação de tais desafios. Os obstáculos para incluir novas vacinas com mais antígenos permanecem visíveis em partes desses países, onde doenças imunopreveníveis em lactentes continuam a ser um grande problema. Os desafios incluem a heterogeneidade da cobertura vacinal dentro de cada país e nos países vizinhos, o que pode contribuir para baixas taxas de cobertura vacinal; o impacto adverso da migração interna de pessoas não vacinadas, o que favoreceu o ressurgimento de doenças imunopreveníveis; a escassez de vacinas; e o impacto da pandemia de síndrome respiratória aguda grave do coronavírus 2 (SARS-CoV-2) e mudanças relacionadas nos recursos de atenção à saúde. Para melhorar a cobertura das vacinas pediátricas na Colômbia e no Peru, será necessário assegurar sua integração generalizada em esquemas de vacinas combinadas contendo antígenos de difteria, tétano, pertussis acelular, poliovírus inativado, Haemophilus influenzae tipo B e hepatite B, com uma série primária de três doses aplicadas aos 2, 4 e 6 meses de idade seguidas de um reforço aos 18 meses de idade. Tais vacinas desempenham papéis importantes na prevenção da difteria, tétano e coqueluche; na erradicação da poliomielite; e no reforço contra H. influenzae tipo b.
ABSTRACT
[ABSTRACT]. The objective of this article was to consider the vaccination challenges in Colombia and Peru and the role of pediatric combination vaccines in overcoming these challenges. Barriers to including new vaccines with more antigens remain apparent in parts of these countries, where vaccine-preventable diseases in infants continue to be a major problem. The challenges include the heterogeneity of vaccine coverage within each country and in neighboring countries, which can contribute to poor rates of vaccination coverage; the adverse impact of the inward migration of unvaccinated individuals, which has favored the re-emergence of vaccine-preventable diseases; vaccine shortages; and the impact of the severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) pandemic and the associated shifts in health care resources. To improve the coverage of pediatric vaccines in Colombia and Peru, it will be necessary to ensure the widespread integration into vaccine sched- ules of combination vaccines containing diphtheria, tetanus, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b and hepatitis B antigens with a three-dose primary series delivered at 2, 4 and 6 months of age followed by a booster at 18 months of age. Such vaccines play important roles in preventing diphtheria, tetanus and pertussis; eradicating polio; and providing boosting against H. influenzae type b.
[RESUMEN]. El objetivo de este artículo es considerar los desafíos que se enfrentan en Colombia y Perú con respecto a la vacunación y el papel de las vacunas combinadas pediátricas para superar estos desafíos. Los obstáculos para incluir vacunas nuevas con más antígenos siguen siendo evidentes en algunos lugares de estos países, donde las enfermedades prevenibles por vacunación en menores de 1 año continúan siendo un grave pro- blema. Entre los desafíos se incluye la heterogeneidad de la cobertura de vacunación en cada país y en los países vecinos, lo que puede contribuir con que se registren tasas bajas de cobertura de vacunación; el impacto adverso de la migración interna de personas no vacunadas, lo que ha favorecido la reaparición de enfermedades prevenibles por vacunación; la escasez de vacunas, y el impacto de la pandemia del corona- virus de tipo 2 causante del síndrome respiratorio agudo grave (SARS-CoV-2) y los consiguientes cambios en los recursos de atención médica. Para mejorar la cobertura de las vacunas pediátricas en Colombia y Perú será necesario integrar de manera generalizada en los calendarios de vacunación vacunas combinadas con antígenos de difteria, tétanos, tos ferina acelular, poliovirus inactivados, Haemophilus influenzae tipo b y hepatitis B con una serie primaria de tres dosis administradas a los 2, 4 y 6 meses de edad, seguida de un refuerzo a los 18 meses de edad. Esas vacunas desempeñan un papel esencial en la prevención de la difteria, el tétanos y la tos ferina; la erradicación de la polio; y el refuerzo contra H. influenzae tipo b.
[RESUMO]. O objetivo deste artigo foi avaliar os desafios da vacinação na Colômbia e no Peru e o papel das vacinas pediátricas combinadas na superação de tais desafios. Os obstáculos para incluir novas vacinas com mais antígenos permanecem visíveis em partes desses países, onde doenças imunopreveníveis em lactentes con- tinuam a ser um grande problema. Os desafios incluem a heterogeneidade da cobertura vacinal dentro de cada país e nos países vizinhos, o que pode contribuir para baixas taxas de cobertura vacinal; o impacto adverso da migração interna de pessoas não vacinadas, o que favoreceu o ressurgimento de doenças imu- nopreveníveis; a escassez de vacinas; e o impacto da pandemia de síndrome respiratória aguda grave do coronavírus 2 (SARS-CoV-2) e mudanças relacionadas nos recursos de atenção à saúde. Para melhorar a cobertura das vacinas pediátricas na Colômbia e no Peru, será necessário assegurar sua integração gen- eralizada em esquemas de vacinas combinadas contendo antígenos de difteria, tétano, pertussis acelular, poliovírus inativado, Haemophilus influenzae tipo B e hepatite B, com uma série primária de três doses aplica- das aos 2, 4 e 6 meses de idade seguidas de um reforço aos 18 meses de idade. Tais vacinas desempenham papéis importantes na prevenção da difteria, tétano e coqueluche; na erradicação da poliomielite; e no reforço contra H. influenzae tipo b.
Subject(s)
Vaccines, Combined , Immunization Schedule , Vaccines , Vaccine-Preventable Diseases , Colombia , Peru , Vaccines, Combined , Immunization Schedule , Vaccines , Vaccine-Preventable Diseases , Peru , Vaccines, Combined , Immunization Schedule , Vaccines , Vaccine-Preventable Diseases , ColombiaABSTRACT
ABSTRACT The objective of this article was to consider the vaccination challenges in Colombia and Peru and the role of pediatric combination vaccines in overcoming these challenges. Barriers to including new vaccines with more antigens remain apparent in parts of these countries, where vaccine-preventable diseases in infants continue to be a major problem. The challenges include the heterogeneity of vaccine coverage within each country and in neighboring countries, which can contribute to poor rates of vaccination coverage; the adverse impact of the inward migration of unvaccinated individuals, which has favored the re-emergence of vaccine-preventable diseases; vaccine shortages; and the impact of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic and the associated shifts in health care resources. To improve the coverage of pediatric vaccines in Colombia and Peru, it will be necessary to ensure the widespread integration into vaccine schedules of combination vaccines containing diphtheria, tetanus, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b and hepatitis B antigens with a three-dose primary series delivered at 2, 4 and 6 months of age followed by a booster at 18 months of age. Such vaccines play important roles in preventing diphtheria, tetanus and pertussis; eradicating polio; and providing boosting against H. influenzae type b.
RESUMEN El objetivo de este artículo es considerar los desafíos que se enfrentan en Colombia y Perú con respecto a la vacunación y el papel de las vacunas combinadas pediátricas para superar estos desafíos. Los obstáculos para incluir vacunas nuevas con más antígenos siguen siendo evidentes en algunos lugares de estos países, donde las enfermedades prevenibles por vacunación en menores de 1 año continúan siendo un grave problema. Entre los desafíos se incluye la heterogeneidad de la cobertura de vacunación en cada país y en los países vecinos, lo que puede contribuir con que se registren tasas bajas de cobertura de vacunación; el impacto adverso de la migración interna de personas no vacunadas, lo que ha favorecido la reaparición de enfermedades prevenibles por vacunación; la escasez de vacunas, y el impacto de la pandemia del coronavirus de tipo 2 causante del síndrome respiratorio agudo grave (SARS-CoV-2) y los consiguientes cambios en los recursos de atención médica. Para mejorar la cobertura de las vacunas pediátricas en Colombia y Perú será necesario integrar de manera generalizada en los calendarios de vacunación vacunas combinadas con antígenos de difteria, tétanos, tos ferina acelular, poliovirus inactivados, Haemophilus influenzae tipo b y hepatitis B con una serie primaria de tres dosis administradas a los 2, 4 y 6 meses de edad, seguida de un refuerzo a los 18 meses de edad. Esas vacunas desempeñan un papel esencial en la prevención de la difteria, el tétanos y la tos ferina; la erradicación de la polio; y el refuerzo contra H. influenzae tipo b.
RESUMO O objetivo deste artigo foi avaliar os desafios da vacinação na Colômbia e no Peru e o papel das vacinas pediátricas combinadas na superação de tais desafios. Os obstáculos para incluir novas vacinas com mais antígenos permanecem visíveis em partes desses países, onde doenças imunopreveníveis em lactentes continuam a ser um grande problema. Os desafios incluem a heterogeneidade da cobertura vacinal dentro de cada país e nos países vizinhos, o que pode contribuir para baixas taxas de cobertura vacinal; o impacto adverso da migração interna de pessoas não vacinadas, o que favoreceu o ressurgimento de doenças imunopreveníveis; a escassez de vacinas; e o impacto da pandemia de síndrome respiratória aguda grave do coronavírus 2 (SARS-CoV-2) e mudanças relacionadas nos recursos de atenção à saúde. Para melhorar a cobertura das vacinas pediátricas na Colômbia e no Peru, será necessário assegurar sua integração generalizada em esquemas de vacinas combinadas contendo antígenos de difteria, tétano, pertussis acelular, poliovírus inativado, Haemophilus influenzae tipo B e hepatite B, com uma série primária de três doses aplicadas aos 2, 4 e 6 meses de idade seguidas de um reforço aos 18 meses de idade. Tais vacinas desempenham papéis importantes na prevenção da difteria, tétano e coqueluche; na erradicação da poliomielite; e no reforço contra H. influenzae tipo b.
Subject(s)
Humans , Communicable Disease Control , Vaccines, Combined/administration & dosage , Immunization Programs/standards , Vaccination Coverage , Peru , ColombiaABSTRACT
OBJECTIVE: Community-genotype methicillin-resistant Staphylococcus aureus (CG-MRSA) isolates are known to be more virulent and clinically aggressive in children. The goal of the present study was characterize the molecular epidemiology of MRSA isolates causing infections in Colombian children. METHODS: An observational and prospective study was conducted between April 2009 and June 2011 at 15 hospitals in Bogotá, Colombia. A detailed epidemiological profile was made of 162 children infected with MRSA. The isolates were subjected to antimicrobial susceptibility testing, molecular characterization including 21 virulence genes, SCCmec, spa and agr typing, multilocus sequence typing (MLST), and pulsed-field gel electrophoresis (PFGE). RESULTS: Among all isolates included in the study, 85.8% were obtained from patients whose infectious process was initiated in the community; of these, 69,8% occurred in patients without healthcare-associated risk factors. The molecular characterization of the isolates showed a high proportion (95.1%) containing a community-genotype profile with a high prevalence of SCCmec type IV, PVL-positives, and also related to CC8. Most CG-MRSA isolates (143, 92.9%) were genetically related to the pandemic clone USA300, differing by the presence of SCCmec IVc and the absence of the arginine catabolic mobile element (ACME). CONCLUSIONS: An increase in the frequency of CG-MRSA infections has been reported worldwide. In this study we found that almost all MRSA infections in our pediatric population were caused by community-genotype isolates, supporting the success of the CG-MRSA clones.
Subject(s)
Community-Acquired Infections , Cross Infection , Methicillin-Resistant Staphylococcus aureus/genetics , Staphylococcal Infections/epidemiology , Staphylococcal Infections/microbiology , Anti-Bacterial Agents/pharmacology , Child , Child, Preschool , Colombia/epidemiology , Electrophoresis, Gel, Pulsed-Field , Humans , Methicillin-Resistant Staphylococcus aureus/classification , Methicillin-Resistant Staphylococcus aureus/drug effects , Methicillin-Resistant Staphylococcus aureus/isolation & purification , Microbial Sensitivity Tests , Multilocus Sequence Typing , Prospective StudiesABSTRACT
Introducción. La hepatitis A es una enfermedad infectocontagiosa causada por un virus ARN no encapsulado de la familia Picornaviridae y del género Hepatovirus, que se trasmite por vía fecal-oral, bien sea de persona a persona o en epidemias originadas por una fuente común. Objetivo. Se estimo la seroprevalencia de anticuerpos de tipo IgG contra el virus de la hepatitis A en niños de 1 a 15 años, atendidos en un hospital universitario, como parte de un estudio cooperativo nacional. Métodos. Se realizó un estudio descriptivo y prospectivo, entre junio y noviembre de 2007. Los niveles de anticuerpos se detectaron mediante un inmunoensayo enzimático de micropartículas. A cada participante del estudio se le hizo una encuesta de riesgo con las variables objeto del estudio. Resultados. Se estudiaron 422 niños. La prevalencia global de anticuerpos contra el virus de la hepatitis A fue de 29,1%: 37,1% en el grupo de 5 a 9 años, 36,1%, en el de 10 a 15 y 13,8%, en el de 1 a 4 años. La mayor proporción de prevalencia de anticuerpos se encontró en los niños de estrato socioeconómico más bajo: 44,2% para el estrato 1 y 27,9% para el estrato 2. Discusión. En este estudio se encontró una seroprevalencia de anticuerpos para hepatitis A más baja en menores de 5 años, lo que puede indicar una transición del patrón epidemiológico hacia un nivel intermedio. La prevalencia fue mayor en los niños de estratos socioeconómicos bajos, lo que puede estar en relación con el hacinamiento y las malas prácticas de higiene.
Introduction: Hepatitis A is an infectious disease caused by a non-encapsulated RNA virus of the Picornaviridae family, classified as Hepatovirus. It is transmitted by a fecal-oral route, either from person to person or in common source epidemics. Objective: The aim of this study was to estimate the seroprevalence of IgG antibodies against the hepatitis A virus in children aged 1-15 years, treated in a university hospital as part of a national collaborative study. Methods: A descriptive study was performed between June and November 2007. The antibody titers were detected by means of a Microparticle Capture Enzyme Immunoassay. A survey to identify risk factors was conducted for each participant, with additional variables under study. Results: We studied 422 children. The overall prevalence of antibodies against hepatitis A was 29.1%, with 37.1% in the group of 5 to 9 years of age, 36.1% for 10 to 15, and 13.8% for 1 to 4. The highest proportion of antibody prevalence was found in children of the lowest socioeconomic status, 44.2% for the stratum 1 and 27.9% for the stratum 2. Conclusion: The seroprevalence to hepatitis A virus was lower in children with less than five years of age, which is an indication of a transition of the epidemiological profile to an intermediate one. The prevalence was higher in children of low socioeconomic levels, which may be related to overcrowding and poor hygiene practices.
Subject(s)
Humans , Male , Female , Infant , Child, Preschool , Child , Adolescent , Prevalence , Epidemics , Hepatitis A , RNA Viruses , Immunoglobulin G , Seroepidemiologic Studies , Hepatovirus , Hepatitis A virus , AntibodiesABSTRACT
Teniendo en cuenta que el uso indiscriminado de antibióticos de amplio espectro ha favorecido la aparición de resistencia bacteriana a múltiples drogas, se realizó un estudio de intervención cuasiexperimental entre enero de 2002 y enero de 2006 en la unidad de cuidados intensivos neonatal (UCIN) del Hospital Militar Central de Bogotá (HMC), en el que se restringió el uso de cefalosporinas de 3ª generación cambiándolas por antibióticos no asociados con inducción de beta-lactamasas de espectro extendido (BLEEs), utilizando piperazilina-tazobactam y cefepime. En el estudio se hizo comparación antes y después de la política de restricción antibiótica en infecciones nosocomiales por gérmenes gram negativos, encontrándose que de 2880 pacientes que ingresaron a UCIN, el 24,5% tuvo diagnóstico de infección y de ellos, el 30,7% correspondió a infecciones hospitalarias. De los gérmenes aislados el 49% correspondió a bacterias gram negativas, con una producción de BLEEs en el 51% de los aislados de Klebsiella pneumoniae, de 28% en los de Escherichia coli, de 14% en los de Acinetobacter baumannii y de 7% en los de Serratia. En el 70% de los casos con presencia de BLEEs se habían utilizado cefalosporinas de III generación. Luego de la restricción de cefalosporinas de III generación se observó una importante disminución en los aislamientos de los gérmenes productores de resistencia betalactámica (del 20% en el primer periodo, se bajó a menos del 4% en el segundo), es decir que el riesgo producir BLEEs disminuyó casi cinco veces, con una razón de prevalencia de 4,91(IC 95%: 1,14-21,09) y un valor de p=0,031 respecto al periodo anterior, pudiéndose concluir que la adopción de una política de restricción en el uso de antibióticos tuvo un significativo efecto reductor en la incidencia de BLEEs en la UCIN de nuestro hospital, disminuyendo a su vez los costos, pues se redujo el uso de carbapenems...
Considering that the indiscriminate use of wide spectrum antibiotics has favour the appearance of bacterial resistance to multiple drugs, a quasi-experiemental intervention study was performed between January 2002 and January 2006, in the neonatal intensive care unit (NICU) of the Hospital Militar Central in Bogotá (HMC), in which the use of cephalosporins of 3th generation was restricted and changed for antibiotics non associated with the induction of beta-lactamases of extended spectrum (ESBLs), by the use of piperacillin-tazobactam and cefepime. A comparison was done before and after the restriction policy was applied in nosocomial infections produced by gram-negative bacteria. It was found that 24, 5% out of 2880 patients were diagnose with infections and among them, 30,7% were nosocomial infection. 49% of isolated germs were Gram-negative bacteria from which 51% of Klebsiella pneumoniae, 28% of Escherichia coli, 14% of Acinetobacter baumannii and 7% of Serratia isolates produced ESBLs. In 70% of the ESBLs cases, cephalosporins of 3er generation were used. After restriction of cephalosporins of 3 th generation an important decreased in the number of beta-lactamic resistance isolates were observed (from 20% during the first period to less than 4 % during the second), which means that the risk of ESBLs production decreased five times, with a ratio of prevalence of 4,91 (IC 95%: 1,14-21,09) and a p value of 0,031 with respect to the previous period. It can be conclude that the adoption of a restriction policy in the use of antibiotics had a significant reductor effect on the incidence of ESBLs in NICU of our Hospital, which implies a reduction of costs as the use of carbapenems was also reduced...
Tendo em conta que o uso indiscriminado de antibióticos de amplo espectro favoreceu a aparição de resistência bacteriana a numerosos medicamentos, realizou-se um estudo de intervenção experimental entre janeiro de 2002 e janeiro de 2006 na unidade de terapia intensivos neonatal (UTIN) do Hospital Militar Central de Bogotá, no que se restringiu o uso de cefalosporinas de III geração mudando-as por antibióticos não associados com indução de beta-lactamasas de espectro estendido (BLEEs), utilizando piperazilina-tazobactam e cefepime. No estudo se fez comparação antes e depois da política de restrição antibiótica em infecções nosocomiais por bactérias gram negativos, encontrando-se que de 2880 pacientes que ingressaram a UTIN, o 24,5% teve diagnóstico de infecção e deles, o 30,7% correspondeu a infecções hospitalares. Dos germens isolados o 49% correspondeu a bactérias gram negativas, com uma produção de BLEEs no 51% dos isolados de Klebsiella, de 28% nos de Escherichia coli, de 14% nos de Acinetobacter e de 7% nos de Serratia. No 70% dos casos com presença de BLEEs se tinham utilizado cefalosporinas de III geração. Depois da restrição de cefalosporinas de III geração se observou uma importante diminuição nos isolamentos dos germes produtores de resistência beta-lactámica (do 20% no primeiro período, baixou-se a menos do 4% no segundo), isto é que o risco produzir BLEEs diminuiu quase cinco vezes, com uma razão de prevalência de 4,91(IC 95%: 1,14-21,09) e um valor de p=0,031 com respeito ao período anterior, podendo-se concluir que a adoção de uma política de restrição no uso de antibióticos teve um significativo efeito redutor na incidência de BLEEs na UTIN de nosso hospital, diminuindo a sua vez os custos, pois se reduziu o uso de carbapenems...